Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Consumer Goods, Technology and Consumer Services sectors led shares lower. At the close in...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Healthcare, Technology and Utilities sectors led shares higher while losses in the Basic...
The unmanned aircraft interception systems will include radar and optics, jamming systems and missile and laser capabilities.
Every investor wants to buy into a stock that’s primed for growth. The trick in successful investing is finding those stocks. What makes this difficult is the truth of the...
1. The Boeing CompanyBoeing (NYSE:BA), on the 737 MAX testing on Monday, popped out of a wedge and jumped 24.48, or 14.4%, to 194.49, just a penny off the session high at 194.50,...
It was a week that saw Edge Therapeutics crashing on news of discontinuation of its phase III study, Amgen’s Blincyto getting FDA’s nod for label expansion, EMA...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Neutral | Strong Buy | Neutral |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Sell | Strong Buy | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 146.92 | 147.47 | 145.56 | +0.09 | +0.06% | 53.16M | NASDAQ | |||
| 352.96 | 354.35 | 342.37 | +7.00 | +2.02% | 18.74M | NASDAQ | |||
| 2,844.30 | 2,846.60 | 2,804.80 | +20.0 | +0.71% | 1.14M | NASDAQ | |||
| 36.93 | 37.03 | 36.42 | -0.28 | -0.75% | 122.69K | NYSE | |||
| 43.94 | 44.41 | 43.81 | -0.25 | -0.57% | 16.00M | NYSE | |||
| 74.05 | 74.50 | 73.07 | +0.01 | +0.01% | 12.81M | NASDAQ | |||
| 11.61 | 11.63 | 11.47 | +0.24 | +2.11% | 5.70M | NASDAQ | |||
| 25.82 | 25.90 | 25.40 | +0.07 | +0.27% | 2.83M | NASDAQ | |||
| 27.13 | 27.38 | 27.10 | -0.06 | -0.22% | 24.40M | NYSE | |||
| 84.55 | 85.19 | 84.35 | -0.23 | -0.27% | 849.59K | NYSE | |||
| 88.75 | 88.85 | 86.87 | +2.17 | +2.51% | 755.42K | NYSE | |||
| 220.81 | 221.49 | 218.61 | -4.01 | -1.78% | 20.83M | NASDAQ | |||
| 19.72 | 19.99 | 19.70 | -0.20 | -1.00% | 2.46M | NYSE | |||
| 19.74 | 20.00 | 19.53 | -0.25 | -1.25% | 1.08M | NASDAQ | |||
| 145.08 | 148.00 | 144.57 | -6.11 | -4.04% | 31.53M | NYSE |
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.